4884 Kringle Pharma,Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4884

TSE Growth

Kringle Pharma,Inc.

395

JPY

-1

(-0.25%)

Dec 5, 12:45 pm JST

2.54

USD

Dec 4, 10:45 pm EST

Result

PTS

outside of trading hours

391.1

Dec 5, 10:42 am JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep, 2022	391	-426	-330	-331	-68.3	0	Nov 14, 2022	J-GAAP
Sep, 2023	69	-888	-852	-854	-158.5	0	Nov 13, 2023	J-GAAP
Sep, 2024	80	-817	-754	-756	-118.2	0	Nov 13, 2024	J-GAAP
Sep, 2025	72	-909	-914	-916	-133.9	0	Nov 12, 2025	J-GAAP
Sep, 2026 Guidance	72	-1,172	-1,172	-1,173	-163.2	0	Nov 12, 2025	J-GAAP
YoY	0.0%	-28.9%	-28.2%	-28.1%	-21.9%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Sep, 2021	Dec 28, 2020	206	-1,037	-1,015	-1,017	0*	J-GAAP
	Aug 13, 2021	277	-388	-328	-330	0*	J-GAAP
Results	Nov 12, 2021	289	-357	-299	-301	0*	J-GAAP
Sep, 2022	Nov 12, 2021	Available in future release
	Aug 12, 2022
Results	Nov 14, 2022
Sep, 2023	Nov 14, 2022
Results	Nov 13, 2023
Sep, 2024	Nov 13, 2023
	Aug 9, 2024
Results	Nov 13, 2024
Sep, 2025	Nov 13, 2024
	Jul 16, 2025
Results	Nov 12, 2025
Sep, 2026	Nov 12, 2025	72	-1,172	-1,172	-1,173	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Sep, 2015	ー	－	Available in future release
Sep, 2016	ー	－
Sep, 2017	ー	－
Sep, 2018	ー	－
Sep, 2019	ー	－
Sep, 2020	467	－
Sep, 2021	289	-38.1
Sep, 2022	391	+35.3
Sep, 2023	69	-82.4
Sep, 2024	80	+15.9
Sep, 2025	72	-10.0
Sep, 2026 Guidance	72	0.0	-1,172	-28.9	-1,172	-28.2	-163.2	-21.9

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Sep, 2024	80	-817	-1,021	-36.91	-28.13	0.03	-118.2
Sep, 2025	72	-909	-1,263	-54.39	-37.88	0.03	-133.9
Sep, 2026 Guidance	72	-1,172	-1,628	-91.71	-56.42	0.03	-163.2

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	467	-171	101	100	96.3
Fiscal Year	Sep, 2020	Sep, 2020	Sep, 2016	Sep, 2016	Sep, 2016

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	34	-314	-314	-315	-58.6	0	May 15, 2023	J-GAAP
Oct - Mar, 2023	43	-366	-365	-366	-60.2	0	May 13, 2024	J-GAAP
Oct - Mar, 2024	35	-511	-511	-512	-75.2	0	May 12, 2025	J-GAAP
Oct - Mar, 2025 Guidance	ー	ー	ー	ー	－	0	Nov 12, 2025	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2023	Nov 14, 2022	ー	ー	ー	ー	0	J-GAAP
- - - - Results	May 15, 2023	34	-314	-314	-315	0	J-GAAP
Mar, 2024	Nov 13, 2023	Available in future release
Results	May 13, 2024
Mar, 2025	Nov 13, 2024
Results	May 12, 2025
Mar, 2026	Nov 12, 2025	ー	ー	ー	ー	0	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Sep, 2023	-888	-809	-689	-120	69	1,761	67.27	J-GAAP
Sep, 2024	-817	-782	-661	-121	838	1,816	65.87	J-GAAP
Sep, 2025	-909	-909	-755	-154	84	991	47.67	J-GAAP

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep, 2023	69	-888	-852	-854	-158.5	0	Nov 13, 2023	J-GAAP
Sep, 2024	80	-817	-754	-756	-118.2	0	Nov 13, 2024	J-GAAP
Sep, 2025	72	-909	-914	-916	-133.9	0	Nov 12, 2025	J-GAAP
YoY	-10.0%	-11.3%	-21.2%	-21.2%	-13.3%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	18	-168	-169	-169	-29.5	-933.3	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	25	-198	-196	-197	-32.4	-792.0	May 13, 2024	J-GAAP
Apr - Jun, 2024	18	-213	-152	-152	-24.3	-1,183.3	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	19	-238	-237	-238	-37.2	-1,252.6	Nov 13, 2024	J-GAAP
Oct - Dec, 2024	18	-212	-212	-212	-31.2	-1,177.8	Feb 7, 2025	J-GAAP
Jan - Mar, 2025	17	-299	-299	-300	-44.0	-1,758.8	May 12, 2025	J-GAAP
Apr - Jun, 2025	18	-227	-227	-227	-33.3	-1,261.1	Aug 8, 2025	J-GAAP
Jul - Sep, 2025	19	-171	-176	-177	-25.9	-900.0	Nov 12, 2025	J-GAAP
YoY	0.0%	+28.2%	+25.7%	+25.6%	+30.4%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	94	－	Available in future release
Jan - Mar, 2021	23	－
Apr - Jun, 2021	0	－
Jul - Sep, 2021	172	-57.6
Oct - Dec, 2021	13	-86.2
Jan - Mar, 2022	14	-39.1
Apr - Jun, 2022	85	－
Jul - Sep, 2022	279	+62.2
Oct - Dec, 2022	17	+30.8
Jan - Mar, 2023	17	+21.4
Apr - Jun, 2023	17	-80.0
Jul - Sep, 2023	18	-93.5
Oct - Dec, 2023	18	+5.9
Jan - Mar, 2024	25	+47.1
Apr - Jun, 2024	18	+5.9
Jul - Sep, 2024	19	+5.6
Oct - Dec, 2024	18	0.0
Jan - Mar, 2025	17	-32.0
Apr - Jun, 2025	18	0.0
Jul - Sep, 2025	19	0.0	-171	+28.2	-176	+25.7	-25.9	+30.4

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	406	51	50	50	45.6
Fiscal Year	Sep, 2020	Sep, 2020	Sep, 2020	Sep, 2020	Sep, 2020

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Sep, 2023	363.45	76.7	2,618	2,007	-1,185	ー	Nov 13, 2023	J-GAAP
Sep, 2024	306.87	75.8	2,757	2,089	-756	ー	Nov 13, 2024	J-GAAP
Sep, 2025	182.30	61.5	2,079	1,279	-1,672	ー	Nov 12, 2025	J-GAAP

Kringle Pharma,Inc.(4884) Financial Results